HK Stock Market Move | BAO PHARMA-B (02589) rose nearly 5% against the market trend. The company's drug, Shen Nuo Wa, was previously approved for listing. It has now submitted the KJ017 NDA.

BAO PHARMA-B (02589) rose nearly 5% against the market, up 3.79% at the time of writing, to HK$68.45 with a turnover of HK$183.776 million. In terms of news, recently, BAO PHARMA-B officially listed on the Hong Kong Stock Exchange main board, with a first day closing increase of 138.82%, and the total market value has now exceeded HK$20 billion. According to the prospectus of Baoji Pharmaceutical, the company strategically focuses on four major areas: large-volume subcutaneous drug delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals. The company's pipeline mainly includes 12 independently developed products under research, including three core products (KJ017, KJ103, and SJ02), four other clinical stage candidate drugs (BJ007, KJ015, SJ04, and KJ101), and five pre-clinical assets (BJ008, BJ009, BJ045, BJ047, and BJ044). In the analysis "The Newly-Established 18A of 'Self-Hematopoiesis', BAO PHARMA-B (02659) Constructs Sustainable Growth Sample with 'Three Pillars'", it is pointed out that under the synergy of "scene-driven" strategic selection, technological barriers of synthetic biology, and the industrial advantage of "total cost leadership", Baoji Pharmaceutical has formed its unique "pyramid-shaped" pipeline layout. As the cash flow base, the base of Baoji Pharmaceutical's "pyramid-shaped" pipeline is composed of products with short clinical cycles, low costs, and high market demand certainty, such as the already approved SJ02 and the NDA-submitted KJ017. These products, which focus on addressing specific clinical pain points and technological replacements, can quickly generate stable sales and cash flow, providing the company with the ability of "self-hematopoiesis" and effectively eliminating the "financing anxiety" commonly found in 18A enterprises.